Your search for Warfarin returned 280 results

“The elevation in INR can be explained by the inhibition of CYP2C9 by cannabis use causing decreased metabolism of warfarin,” the authors explained.

Findings seen in warfarin-treated patients with history of international normalized ratio instability

To investigate an appropriate dosing strategy for 4F-PCC (Kcentra; CSL Behring) in obese patients, the authors conducted a retrospective analysis comparing the reversal of warfarin using adjusted (N=28) vs actual body weight (N=50).

Compared with warfarin, apixaban was correlated with reduced risk of major bleeding and intracranial bleeding (adjusted hazard ratios, 0.66 and 0.4, respectively) and dabigatran was correlated with reduced risk of intracranial bleeding (adjusted hazard ratio, 0.45) among patients with atrial fibrillation.

Similar number of out-of-range next INR values for patients with, without extended testing interval

“Repackaging of warfarin sodium tablets into DAAs does not affect the chemical stability,” the authors wrote.

Researchers performed a retrospective cohort study to compare incidence of stroke, bleeding, and myocardial infarction in patients with atrial fibrillation initiating dabigatran or warfarin (n=25,289 for each) from November 2010 to May 2014.

Overall, 808 and 789 patients in the genotype-guided and clinically-guided groups, respectively, completed the trial.

The primary safety endpoint was defined as time to major bleeding events and clinically relevant non-major bleeding events when compared to triple therapy with warfarin.

Patients taking apixaban showed significantly less intracranial hemorrhage (0.33% per year) vs. patients taking warfarin (0.80% per year) no matter the type and location.